Sana Sukhun, Co-Chair of RSG Committee of ASCO for Metastatic Breast Cancer, made the following post on X:
“Aleix Prat discusses promising Asian data especially from Fudan University Shanghai Cancer Centre with antibody drug conjugate SHR-A1811 demonstrating non-inferiority to the standard quadruple therapy in early Breast Cancer.”
